Turn Therapeutics Inc. Research and Development Expense
Turn Therapeutics Inc. (TTRX) reported Research and Development Expense of $475.06 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Turn Therapeutics Inc. research and development expense for the quarter ending 2026-06-30 was $475.06K, a 657.94% increase year-over-year.
- Turn Therapeutics Inc. research and development expense for the quarter ending 2026-03-31 was $109.43K, a 1081.92% increase year-over-year.
- Turn Therapeutics Inc. research and development expense for the quarter ending 2025-12-31 was $34.93K, a 257.71% increase year-over-year.
- Turn Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $158.70K, a 3.53% increase year-over-year.
- Turn Therapeutics Inc. research and development expense for fiscal 2025 was $265.57K, a 7.97% increase from fiscal 2024.
- Turn Therapeutics Inc. research and development expense for fiscal 2024 was $245.96K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $475.06K 10-Q · filed 2026-08-12 | $584.50K 10-Q · filed 2026-08-12 | $619.43K derived: sum of 3 quarters · filed 2026-08-12 | $778.13K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $109.43K 10-Q · filed 2026-05-11 | $144.37K derived: sum of 2 quarters · filed 2026-05-11 | $303.07K derived: sum of 3 quarters · filed 2026-05-11 | $365.75K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $34.93K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $193.63K derived: sum of 2 quarters · filed 2026-03-31 | $256.31K derived: sum of 3 quarters · filed 2026-08-12 | $265.57K 10-K · filed 2026-03-31 |
| 2025-09-30 | $158.70K 10-Q · filed 2025-11-13 | $221.38K derived: sum of 2 quarters · filed 2026-08-12 | $230.64K 10-Q · filed 2025-11-13 | $240.40K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $62.68K 10-Q · filed 2026-08-12 | $71.94K 10-Q · filed 2026-08-12 | $81.70K derived: sum of 3 quarters · filed 2026-08-12 | $234.99K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $9.26K 10-Q · filed 2026-05-11 | $19.02K derived: sum of 2 quarters · filed 2026-05-11 | $172.31K derived: sum of 3 quarters · filed 2026-05-11 | |
| 2024-12-31 | $9.77K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $163.05K derived: sum of 2 quarters · filed 2026-03-31 | $245.96K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $153.28K 10-Q · filed 2025-11-13 | $236.19K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |